Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination
Juan M. Schvartzman, Grace Forsyth, Henry Walch, et al.
Molecular Cell (2023) Vol. 83, Iss. 13, pp. 2347-2356.e8
Open Access | Times Cited: 23

Showing 23 citing articles:

Emerging roles of nucleotide metabolism in cancer
Diana D. Shi, Milan R. Savani, Kalil G. Abdullah, et al.
Trends in cancer (2023) Vol. 9, Iss. 8, pp. 624-635
Open Access | Times Cited: 32
BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethality
Xin Li, Lee Zou
Journal of Clinical Investigation (2024) Vol. 134, Iss. 14
Open Access | Times Cited: 13
Roles of chromatin and genome instability in cellular senescence and their relevance to ageing and related diseases
Zeming Wu, Jing Qu, Guang‐Hui Liu
Nature Reviews Molecular Cell Biology (2024) Vol. 25, Iss. 12, pp. 979-1000
Closed Access | Times Cited: 7
Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomas
Matthew S. Waitkus, Elise N. Erman, Zachary J. Reitman, et al.
Neuro-Oncology (2024) Vol. 26, Iss. 6, pp. 1012-1024
Closed Access | Times Cited: 6
Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1
Anna D. Staniszewska, Domenic Pilger, Sonja J. Gill, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 7, pp. 1338-1351
Closed Access | Times Cited: 14
DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology
Rifaquat Rahman, Diana D. Shi, Zachary J. Reitman, et al.
Neuro-Oncology (2024)
Open Access | Times Cited: 5
Metabolism-driven chromatin dynamics: Molecular principles and technological advances
Varun Sahu, Chao Lü
Molecular Cell (2025) Vol. 85, Iss. 2, pp. 262-275
Closed Access
PARP inhibition-associated heterochromatin confers increased DNA replication stress and vulnerability to ATR inhibition in SMARCA4-deficient cells
Kimiyoshi Yano, Megumi Kato, Satoshi Endo, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
D-2-hydroxyglutarate impairs DNA repair through epigenetic reprogramming
Fengchao Lang, Karambir Kaur, Haiqing Fu, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Lipoylation inhibition enhances radiation control of lung cancer by suppressing homologous recombination DNA damage repair
Jui‐Chung Chiang, Zeng‐Fu Shang, Tracy I. Rosales, et al.
Science Advances (2025) Vol. 11, Iss. 11
Closed Access
20 years of histone lysine demethylases: From discovery to the clinic and beyond
Zach H. Gray, M. Honer, Pooja Ghatalia, et al.
Cell (2025) Vol. 188, Iss. 7, pp. 1747-1783
Closed Access
Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability
Kathryn Gunn, Julie-Aurore Losman
Cold Spring Harbor Perspectives in Medicine (2024) Vol. 14, Iss. 5, pp. a041537-a041537
Closed Access | Times Cited: 4
Treatment of IDH-mutant glioma in the INDIGO era
Mathew D. Lin, Alexander C.-Y. Tsai, Kalil G. Abdullah, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 4
DNA damage in IDH-mutant gliomas: mechanisms and clinical implications
Diana D. Shi, Soummitra Anand, Kalil G. Abdullah, et al.
Journal of Neuro-Oncology (2022) Vol. 162, Iss. 3, pp. 515-523
Closed Access | Times Cited: 17
Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors
Yosuke Kitagawa, Ami Kobayashi, Daniel P. Cahill, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 3, pp. 189102-189102
Closed Access | Times Cited: 2
Therapeutic Targeting of DNA Repair Pathways in Pediatric Extracranial Solid Tumors: Current State and Implications for Immunotherapy
Sophia Zhao, Daniel Prior, Christine M. Heske, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1648-1648
Open Access | Times Cited: 2
How to sensitize glioblastomas to temozolomide chemotherapy: a gap-centered view
Alila Miramova, Anton Gartner, Dmitri Ivanov
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 2
Oncogenic IDH1 mut drives robust loss of histone acetylation and increases chromatin heterogeneity
Noa Furth, Niv Cohen, Avishay Spitzer, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 122, Iss. 1
Open Access | Times Cited: 1
Deciphering the Multifaceted Roles and Clinical Implications of 2-Hydroxyglutarate in Cancer
Jie Hao, Ziyi Huang, Siyue Zhang, et al.
Pharmacological Research (2024) Vol. 209, pp. 107437-107437
Open Access
Tolerance of Oncogene-Induced Replication Stress: A Fuel for Genomic Instability
Taichi Igarashi, Kimiyoshi Yano, Satoshi Endo, et al.
Cancers (2024) Vol. 16, Iss. 20, pp. 3507-3507
Open Access
Phase 2 Trial of Veliparib, Local Irradiation and Temozolomide in Patients with Newly Diagnosed High-Grade Glioma: A Children's Oncology Group Study
Matthias A. Karajannis, Arzu Onar‐Thomas, Tong Lin, et al.
Neuro-Oncology (2024)
Closed Access
DNA hypomethylation promotes UHRF1-and SUV39H1/H2-dependent crosstalk between H3K18ub and H3K9me3 to reinforce heterochromatin states
Yanqing Liu, Joel Hrit, Alison A. Chomiak, et al.
Molecular Cell (2024)
Open Access
Heterochromatin-Dependent Replication Stress: A Lesson from IDH1/2 Mutants
Lee Zou
Cancer Research (2023) Vol. 83, Iss. 18, pp. 2987-2989
Closed Access | Times Cited: 1
Page 1

Scroll to top